| 5.24 0.07 (1.35%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.66 | 1-year : | 7.56 |
| Resists | First : | 5.7 | Second : | 6.48 |
| Pivot price | 5.3  |
|||
| Supports | First : | 4.44 | Second : | 3.7 |
| MAs | MA(5) : | 4.84  |
MA(20) : | 5.5 |
| MA(100) : | 6.92 |
MA(250) : | 9.22 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 28.7 |
D(3) : | 18.1 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 13.88 | Low : | 4.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CERT ] has closed above bottom band by 47.7%. Bollinger Bands are 73.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.29 - 5.3 | 5.3 - 5.32 |
| Low: | 5.01 - 5.03 | 5.03 - 5.05 |
| Close: | 5.21 - 5.24 | 5.24 - 5.27 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Mon, 25 May 2026
Bronstein, Gewirtz & Grossman, LLC Encourages Certara, Inc. (CERT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Mon, 25 May 2026
CERT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Sun, 24 May 2026
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm - Caledonian Record
Sun, 24 May 2026
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Fri, 22 May 2026
Certara, Inc. (CERT) Q1 earnings miss estimates - MSN
Thu, 21 May 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 156 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 112.2 (%) |
| Shares Short | 24,120 (K) |
| Shares Short P.Month | 22,290 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.67 |
| Profit Margin | -3.6 % |
| Operating Margin | 3.7 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | -1.5 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 1.66 |
| Sales Per Share | 2.69 |
| EBITDA (p.s.) | 0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 91 (M) |
| Levered Free Cash Flow | 117 (M) |
| PE Ratio | -52.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 1.94 |
| Price to Cash Flow | 8.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|